Fibrinogen Concentrates Market by Product Type (Human Fibrinogen Concentrates, Animal-Derived Fibrinogen Concentrates), by Application (Congenital Fibrinogen Deficiency Treatment, Acquired Fibrinogen Deficiency Treatment, Cardiovascular Surgery), by End-Use Industry (Hospitals & Clinics, Ambulatory Surgical Centers); Global Insights & Forecast (2024 - 2030)

As per Intent Market Research, the Fibrinogen Concentrates Market was valued at USD 1.4 Billion in 2023 and will surpass USD 2.3 Billion by 2030; growing at a CAGR of 7.4% during 2024 - 2030.

The fibrinogen concentrates market is experiencing significant growth, driven by increasing incidences of coagulation disorders and advancements in surgical procedures. Fibrinogen concentrates are critical in managing bleeding complications, especially in patients with congenital or acquired fibrinogen deficiencies. With rising awareness about these products among healthcare providers, the market has expanded its reach across various applications and end-use industries. This content explores the key segments, highlighting the largest and fastest-growing subsegments within product types, applications, and end-use industries, alongside a regional analysis and competitive landscape.

Human Fibrinogen Concentrates Are Largest Product Type Owing to High Efficacy

Human fibrinogen concentrates dominate the product type segment due to their proven efficacy in managing bleeding disorders. These products are derived from human plasma and are widely preferred for treating both congenital and acquired fibrinogen deficiencies. Their reliability in critical surgical settings and emergency bleeding control has made them the cornerstone of fibrinogen replacement therapy.

The growing prevalence of bleeding disorders, coupled with advancements in plasma fractionation technologies, has fueled the demand for human fibrinogen concentrates. As healthcare systems continue to prioritize effective coagulation management, this subsegment is expected to retain its leading position in the market.

Cardiovascular Surgery Is Fastest Growing Application Due to Rising Surgical Interventions

Cardiovascular surgery is the fastest-growing application segment in the fibrinogen concentrates market. The rising prevalence of cardiovascular diseases and the increasing number of complex surgical interventions have heightened the need for effective blood management solutions. Fibrinogen concentrates play a pivotal role in minimizing bleeding risks during surgeries, ensuring better patient outcomes.

Advancements in surgical techniques and the growing adoption of fibrinogen concentrates as part of perioperative care protocols are driving this segment's growth. As the global burden of cardiovascular diseases continues to rise, the demand for fibrinogen concentrates in this application is projected to grow rapidly.

Hospitals and Clinics Are Largest End-Use Industry Due to Comprehensive Care

Hospitals and clinics represent the largest end-use industry for fibrinogen concentrates, driven by their ability to offer comprehensive care for bleeding disorders and surgical interventions. These healthcare facilities are primary points of treatment for patients requiring fibrinogen replacement therapy, particularly in emergency and critical care settings.

The increasing number of hospitals equipped with advanced diagnostic and treatment facilities, coupled with a growing patient base requiring coagulation management, has solidified their position as the leading end-user. The centralized procurement processes in hospitals also facilitate bulk adoption of fibrinogen concentrates, further boosting their market share.

North America Is Largest Region Due to Advanced Healthcare Infrastructure

North America leads the fibrinogen concentrates market, primarily owing to its advanced healthcare infrastructure and high prevalence of coagulation disorders. The region benefits from well-established reimbursement policies and widespread awareness among healthcare providers regarding the use of fibrinogen concentrates in managing bleeding complications.

The U.S., in particular, dominates the North American market, supported by extensive research and development activities and the presence of key market players. With a rising number of cardiovascular surgeries and improved diagnostic capabilities, North America is expected to maintain its leadership position in the global market.

Competitive Landscape and Leading Companies

The fibrinogen concentrates market is characterized by the presence of key players focusing on innovation and strategic collaborations. Prominent companies include CSL Behring, Octapharma AG, and LFB Group, known for their robust product portfolios and global reach. These companies are investing heavily in research and development to improve product efficacy and expand indications for fibrinogen concentrates.

The competitive landscape is further shaped by partnerships with healthcare providers and advancements in plasma fractionation technologies. As demand for fibrinogen concentrates continues to grow, market players are likely to focus on geographic expansion and the development of next-generation products to gain a competitive edge.

Recent Developments:

• CSL Behring launched a next-generation fibrinogen concentrate product designed for improved solubility and faster administration.
• Octapharma AG announced the expansion of its manufacturing facilities to increase production capacity for fibrinogen concentrates.
• Grifols S.A. received FDA approval for a new indication of its fibrinogen concentrate product in managing trauma-induced hemorrhage.
• LFB Group partnered with a leading research institute to develop advanced formulations of fibrinogen concentrates for surgical applications.
• Takeda Pharmaceutical Company introduced a high-purity fibrinogen concentrate product targeting rare bleeding disorders in emerging markets.

List of Leading Companies:

• Baxter International Inc.
• Biotest AG
• BPL (Bio Products Laboratory)
• CSL Behring
• Green Cross Corporation
• Grifols S.A.
• Hualan Biological Engineering Inc.
• Kedrion Biopharma
• LFB Group
• Octapharma AG
• ProFibrix BV
• Sanquin Plasma Products
• Shanghai RAAS Blood Products Co., Ltd.
• Shire (now part of Takeda)
• Takeda Pharmaceutical Company

Report Scope: